| |
Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients, by Baseline Demographics
|
| |
| |
Reported by Jules Levin
IDWeek 2014
Philadelphia, PA
October 8-12, 2014
Ronald G. Nahass1*, John Vierling2, Hans Van Vlierberghe3, David Wyles4, Maurizia Rossana Brunett o5, Wangang Xie6, Daniel Cohen6, Yan Luo6, Jeff rey Enejosa6
1ID Care, Hillsborough, New Jersey, United States; 2Baylor-St. Luke's Medical Center/St. Luke's Advanced Liver Therapies, Houston, Texas, United States; 3Ghent University Hospital, Ghent, Belgium; 4UCSD Anti viral Research Center, San Diego, California, United States; 5Liver Unit, University Hospital of Pisa, Pisa, Italy; 6AbbVie Inc., North Chicago, Illinois, United States
*Presenting author
PEARL-II: RANDOMIZED PHASE 3 TRIAL OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333 WITH OR WITHOUT RIBAVIRIN IN HEPATITIS C VIRUS GENOTYPE 1B-INFECTED, TREATMENT-EXPERIENCED PATIENTS.....http://www.natap.org/2014/DDW/DDW_08.htm
PEARL-III: 12 Weeks of ABT-450/r/267 + ABT-333 Achieved SVR in >99% of 419 Treatment-naïve HCV Genotype 1b-Infected Adults With or Without Ribavirin......http://www.natap.org/2014/EASL/EASL_59.htm
PEARL-IV: A 12-week Regimen of ABT-450/r/ABT-267 and ABT-333, With or Without Ribavirin Achieves SVR12 Rates ≥90% in Treatment-naïve Adults Infected With Hepatitis C Virus Genotype 1a.....http://www.natap.org/2014/DDW/DDW_01.htm
|
|
| |
| |
|
|
|
